Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamoxifen + tegafur
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination anticancer therapy consisting of tamoxifen and tegafur. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in breast tissue, while tegafur is a prodrug that converts to 5-fluorouracil (5-FU) in the body. This combination is used primarily for the treatment of node-positive breast cancer, particularly in estrogen receptor-positive patients.
- Other names
- TUFTTU
02
Targets
ESR1 (ERα)ESR2 (ERβ)TS (Thymidylate synthase)
Beyond the preview
Go deeper on tamoxifen + tegafur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamoxifen + tegafur.